Clinical Trial Update: Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

View source ↗

Summary

This ClinicalTrials.gov update describes a study evaluating the systemic anti-tumor activity and safety of combining SBRT with concurrent PD-1 blockade for meta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• PD-1 blockade

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC | Status: RECRUITING